EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside

Elif Çakan, Olivia D Lara iD, Anna Szymanowska iD, Emine Bayraktar, Arturo Chavez-Reyes, Gabriel Lopez-Berestein, Paola Amero iD, Cristian Rodriguez-Aguayo iD

Cancers · 23.08.2024 · 16 (17) · 2940

DOI: 10.3390/cancers16172940 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.08.2024. Verfasst von Elif Çakan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 283 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Narodowa Agencja Wymiany Akademickiej, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advancements in our comprehension of tumor biology and chemoresistance have spurred the development of treatments that precisely target specific molecules within the body. Despite the expanding landscape of therapeutic options, there persists a demand for innovative approaches to address unmet clinical needs. RNA therapeutics have emerged as a promising frontier in this realm, offering novel avenues for intervention such as RNA interference and the utilization of antisense oligonucleotides (ASOs). ASOs represent a versatile class of therapeutics capable of selectively targeting messenger RNAs (mRNAs) and silencing disease-associated proteins, thereby disrupting pathogenic processes at the molecular level. Recent advancements in chemical modification and carrier molecule design have significantly enhanced the stability, biodistribution, and intracellular uptake of ASOs, thereby bolstering their therapeutic potential. While ASO therapy holds promise across various disease domains, including oncology, coronary angioplasty, neurological disorders, viral, and parasitic diseases, our review manuscript focuses specifically on the application of ASOs in targeted cancer therapies. Through a comprehensive examination of the latest research findings and clinical developments, we delve into the intricacies of ASO-based approaches to cancer treatment, shedding light on their mechanisms of action, therapeutic efficacy, and prospects.

Schlagwörter

Stichwörter der Autor:innen

Grb2antisense oligonucleotide delivery systemantisense oligonucleotidescancer therapynon-coding RNA

Autor:innen und Institutionen

  • Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
  • Faculty of Medicine, Hacettepe University, Ankara 06100, Turkey.
  • Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
  • Division of Gynecologic Oncology, University of North Carolina, Chapel Hill, NC 27599, USA.
  • Department of Medical Biology, Faculty of Medicine, University of Gaziantep, Gaziantep 27310, Turkey.
  • Medical School, Universidad Finis Terrae, Santiago de Chile 7501014, Chile.

ORCID-Profile: Olivia D Lara, Anna Szymanowska, Paola Amero, Cristian Rodriguez-Aguayo

Förderung

  • NCI NIH HHS
  • Narodowa Agencja Wymiany Akademickiej
  • NIH HHS
  • NIH institutional training grant
  • MD Anderson Cancer Center Support Grant
  • Polish National Agency for Academic Exchange (NAWA)

Zitieren

APA

Çakan, E., Lara, O. D., Szymanowska, A., Bayraktar, E., Chavez-Reyes, A., Lopez-Berestein, G., Amero, P., & Rodriguez-Aguayo, C. (2024). Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside. Cancers, 16(17), 2940. https://doi.org/10.3390/cancers16172940

Vancouver

Çakan E, Lara OD, Szymanowska A, Bayraktar E, Chavez-Reyes A, Lopez-Berestein G, et al. Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside. Cancers. 2024;16(17):2940. doi:10.3390/cancers16172940

BibTeX
@article{akan2024,
  author = {Çakan, Elif and Lara, Olivia D and Szymanowska, Anna and Bayraktar, Emine and Chavez-Reyes, Arturo and Lopez-Berestein, Gabriel and Amero, Paola and Rodriguez-Aguayo, Cristian},
  title = {Therapeutic Antisense Oligonucleotides in Oncology: From Bench to Bedside},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {17},
  pages = {2940},
  doi = {10.3390/cancers16172940}
}
Kostenlos starten →